Share
clock Created with Sketch. 19/01/16
17:40
Share
Originally posted by waynesworld
↑
Interestingly, it would appear that TEN-010 could never have been considered for Grand Challenge 6 funded by CRUK. The Grand Challenge Advisory Panel will only consider applications which ' focus upon targeting the Myc protein itself'. As far as I understand, the drug acquired by Roche doesn't directly target Myc but rather targets one of the collaborators of Myc - a bromodomain inhibitor.
Expand
Conflict of interest now but maybe after the grants are suggested we could find our next Board member in the advisory panel. I vote for this guy -http://www.cancerresearchuk.org/fun...rand-challenge-award/panels#members_gallery_6
Last edited by
ds :
19/01/16
(20min delay)